Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...
Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...
7h
THE cold weather can trigger a range of symptoms, with the most common being shivering. But if certain symptoms seem out of ...
The Montair LC tablet is an antiallergic tablet that relieves sneezing, itching, watery eyes, stuffy nose, and runny nose ...
"I am excited to see the preliminary clinical data which demonstrated that treatment with briquilimab ... additional studies of briquilimab in chronic urticaria." "We are very pleased to present ...
Citi keeps a Buy rating on Celldex (CLDX) with a $70 price target after after Jasper Therapeutics (JSPR) reported preliminary data from its ...
Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...
Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...
Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...
The Amazing Times on MSN3h
Five Common Medications That May Increase Your Risk of DementiaDementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback